FDANews
FDAnews Drug Daily Bulletin

Study Shows Frequent Bias in Published Breast Cancer Trials

Jan. 16, 2013
An analysis of 164 phase III breast cancer trials shows bias in reporting the primary endpoint and toxicity results. Thirty-three percent of the trials published between 1995 and 2011 exhibited biased reporting of the prespecified primary endpoint. Sixty-seven percent showed bias in reporting toxicity rates.
Cancer Network